| Co-Investigator(Kenkyū-buntansha) |
HUH Namho 岡山大学, 大学院・医歯薬学総合研究科, 教授 (70142023)
WATANABE Masami 岡山大学, 岡山大学病院, 准教授 (70444677)
SAKAGUCHI Masakiyo 岡山大学, 大学院・医歯薬学総合研究科, 准教授 (70379840)
KAKU Haruki 岡山大学, 岡山大学病院, 講師 (60346426)
UEKI Hideo 岡山大学, 医学部, 技術専門職員 (90537218)
|
|---|
| Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2013: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2012: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2011: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Research Abstract |
In situ gene therapy with tumor suppressor, REIC/Dkk-3, induces cancer-specific apoptosis and activation of anti-cancer immune. The combined effects seem to be important for the therapeutic outcomes of personalized-cancer vaccination. In this study, we elucidated that the suppressive effect of REIC/Dkk-3 on the differentiation of MDSC and the following CTL activation are important for the mechanism of the personalized-cancer vaccination.
|
